Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­ : ¾à¹° Á¾·ùº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel, and Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1586431
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 118 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ¼¼°è ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 78¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¶»ç º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀåÀº Èí¿¬·® Áõ°¡, ÁÂ½Ä »ýȰ½À°ü µî »ýȰ½À°ü º¯È­, ¿À¿°¹°Áú ³ëÃâ Áõ°¡¿¡ ÀÇÇØ Å©°Ô °ßÀεǰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀº °ø±â Áú ÀúÇÏ¿Í °Ç°­¿¡ ÇØ·Î¿î »ýȰ ½À°üÀÌ È£Èí±â °Ç°­¿¡ ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ IPF¸¦ Æ÷ÇÔÇÑ Æó ÁúȯÀÇ ¹ßº´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ¯¹ß¼º Æó¼¶À¯Áõ°ú ±× À§Çè ¿äÀο¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼­ Á¶±â Áø´Ü°ú Á¶±â Ä¡·á¸¦ Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ¶óÀÌÇÁ½ºÅ¸ÀÏÀÌ °è¼Ó º¯È­ÇÔ¿¡ µû¶ó È¿°úÀûÀΠƯ¹ß¼º Æó¼¶À¯Áõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä´Â ÇâÈÄ ¸î ³â µ¿¾È Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Ư¹ß¼º Æó¼¶À¯Áõ À¯º´·üÀÇ Áõ°¡´Â Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹ ±¹¸³º¸°Ç¿ø¿¡ µû¸£¸é 2021³â Ư¹ß¼º Æó¼¶À¯Áõ À¯º´·üÀº Àα¸ 10¸¸ ¸í´ç 36¸íÀÎ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ÀνÄÀÇ Çâ»ó°ú Áø´Ü ¹æ¹ýÀÇ °³¼±À¸·Î ÁúȯÀÇ Á¶±â ¹ß°ßÀÌ ¿ëÀÌÇØÁö¸é¼­ Ä¡·á¸¦ ¿øÇϴ ȯÀÚÃþÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î Ư¹ß¼º Æó¼¶À¯Áõ À¯º´·ü Áõ°¡¿Í Áø´Ü ¹æ¹ýÀÇ ¹ßÀüÀº È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô Áõ°¡½ÃÄÑ ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.

Ư¹ß¼º Æó¼¶À¯ÁõÀº ³ë³âÃþÀÌ Æ¯È÷ Ãë¾àÇÑ ÁúȯÀ¸·Î, Àü ¼¼°èÀûÀ¸·Î ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀåÀ» Å©°Ô °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¬ÇÕ(EU)ÀÇ °æ¿ì Àα¸ÀÇ 21.3% ÀÌ»óÀÌ 65¼¼ ÀÌ»óÀ¸·Î È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àα¸ Ãß¼¼´Â Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ Å©°Ô Áõ°¡½Ãų °¡´É¼ºÀÌ ³ô½À´Ï´Ù.

Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀå º¸°í¼­ - ÁÖ¿ä ³»¿ë

Åõ¿© °æ·Îº°·Î´Â °æ±¸¿ë ¾à¹°ÀÌ ¿¹Ãø ±â°£ µ¿¾È ¼¼°è ½ÃÀå¿¡¼­ Å« CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº »ç¿ë ÆíÀǼº ¹× ¿Ü·¡ ȯÀÚ °ü¸® °¡´É¼º°ú °°Àº ¸î °¡Áö ÀåÁ¡¿¡ ±âÀÎÇÕ´Ï´Ù.

À¯Åë ä³Îº°·Î´Â º´¿ø ¾à±¹ ºÎ¹®ÀÌ ÀÔ¿øÀ² Áõ°¡¿Í °íµµÀÇ Ä¡·á°¡ ÇÊ¿äÇÑ È¯ÀÚ¸¦ À§ÇÑ Àü¹® ÀÇ·á ¼­ºñ½º Á¦°øÀ¸·Î ÀÎÇØ 2024³â ½ÃÀå¿¡¼­ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

2024³â Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ¼¼°è ½ÃÀå¿¡¼­ ºÏ¹Ì°¡ ¼±ÁøÈ­µÈ ÀÇ·á ÀÎÇÁ¶ó·Î ÀÎÇØ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

Àεµ Ư¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀåÀº ÀǾàǰ Á¦Á¶ ºÎ¹®¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ÁÖ¿ä ±â¾÷À¸·Î´Â F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Medicinova, Inc, Merck &Co, Inc, Galapagos NV, Novartis AG, Novartis AG, Fibrogen, Inc. Galapagos NV, Novartis AG, Fibrogen, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ Æ¯¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ Æ¯¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀå : ¾à¹° Á¾·ùº°

Á¦6Àå ¼¼°èÀÇ Æ¯¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀå : Åõ¿© °æ·Îº°

Á¦7Àå ¼¼°èÀÇ Æ¯¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

Á¦8Àå ¼¼°èÀÇ Æ¯¹ß¼º Æó¼¶À¯Áõ Ä¡·á ½ÃÀå : Áö¿ªº°

Á¦9Àå °æÀï »óȲ

Á¦10Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The global idiopathic pulmonary fibrosis treatment market size is expected to reach USD 7.81 billion by 2034, according to a new study by Polaris Market Research. The report "Idiopathic Pulmonary Fibrosis Treatment Market Size, Share, Trends, Industry Analysis Report: By Drug Class, Route of Administration, Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The idiopathic pulmonary fibrosis treatment market is significantly driven by changing lifestyle habits, such as rising smoking consumption and sedentary behavior, as well as increasing exposure to pollutants. These factors contribute to the rising incidence of lung diseases, including IPF, as poor air quality and unhealthy habits impact respiratory health. Additionally, the growing awareness of idiopathic pulmonary fibrosis and its risk factors encourages earlier diagnosis and treatment. As lifestyles continue to evolve, the demand for effective idiopathic pulmonary fibrosis therapies is expected to rise in the coming years.

The rising prevalence of idiopathic pulmonary fibrosis is driving the growth of the idiopathic pulmonary fibrosis treatment market. According to the National Institutes of Health, the prevalence of idiopathic pulmonary fibrosis was 36 cases per 100,000 people in 2021. The growing awareness and improving diagnostic methods facilitate earlier disease identification, expanding the patient population seeking treatment. Consequently, the combination of increasing idiopathic pulmonary fibrosis prevalence and advancements in diagnostics is significantly boosting demand for effective treatment options, positively impacting the market growth.

The growing number of geriatrics worldwide is expected to significantly drive the idiopathic pulmonary fibrosis treatment market during the forecast period, as older adults are particularly susceptible to the disease. In the European Union, over 21.3% of the population is aged 65 and older, highlighting the increasing demand for effective treatments. This demographic trend will likely lead to a substantial rise in the need for idiopathic pulmonary fibrosis therapies.

Idiopathic Pulmonary Fibrosis Treatment Market Report Highlights

Based on route of administration, the oral segment is anticipated to register a significant CAGR in the global market during the forecast period. This growth is attributed to its several advantages, including ease of use and potential of outpatient management.

By distribution channel, the hospital pharmacies segment accounted for the largest revenue share of the market in 2024 due to increasing hospitalization rates and the availability of specialized care for patients requiring advanced treatments.

In 2024, North America accounted for the largest revenue share of the global idiopathic pulmonary fibrosis treatment market due to its advanced medical infrastructure

The idiopathic pulmonary fibrosis treatment market in India is projected for significant growth during the forecast period due to the increased investments in its pharmaceutical manufacturing sector.

A few global key market players are F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Medicinova, Inc; Merck & Co., Inc.; Galapagos NV; Novartis AG; and Fibrogen, Inc.

Polaris Market Research has segmented the idiopathic pulmonary fibrosis treatment market report on the basis of drug class, route of administration, distribution channel, and region:

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

By Regional Outlook (Revenue - USD Billion, 2020-2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Idiopathic Pulmonary Fibrosis Treatment Market Insights

5. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Class

6. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Route of Administration

7. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Distribution Channel

8. Global Idiopathic Pulmonary Fibrosis Treatment Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â